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Abstract 
Rocuronium (ROC) and Vecuronium (VEC) are the most currently used steroidal 
non-depolarizing neuromuscular blocking (MNB) agents. Sugammadex (SUG) rapidly reverses 
steroidal NMB agents after anaesthesia. The present study was conducted in order to evaluate 
neuronal effects of SUG alone and in combination with both ROC and VEC. Using MTT, CASP-3 
activity and Western-blot we determined the toxicity of SUG, ROC or VEC in neurons in primary 
culture. SUG induces apoptosis/necrosis in neurons in primary culture and increases cytochrome 
C (CytC), apoptosis-inducing factor (AIF), Smac/Diablo and Caspase 3 (CASP-3) protein 
expression. Our results also demonstrated that both ROC and VEC prevent these SUG effects. 
The protective role of both ROC and VEC could be explained by the fact that SUG encapsulates 
NMB drugs. In BBB impaired conditions it would be desirable to control SUG doses to prevent the 
excess of free SUG in plasma that may induce neuronal damage. A balance between SUG, ROC or 
VEC would be necessary to prevent the risk of cell damage. 
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Introduction 
NMB drugs are used to obtain skeletal muscle 
relaxation in order to enable endotracheal intubation, 
facilitate mechanical ventilation and prevent patient 
from moving to assure optimal surgical conditions 
[1,2]. ROC and VEC are the most currently used 
steroidal non-depolarizing MNB agents [1,3,4,5] 
acting as competitive antagonists to acetylcholine 
(Ach) for binding to the nicotinic receptor at the 
neuromuscular junction [6,7,8]. After tracheal 
extubation, residual NMB may result in pulmonary 
complications, airway obstruction and increased 
morbidity. In this sense, pharmacological reversion of 
NMB is a useful tool to prevent post-anaesthetic 
complications [9,10]. Sugammadex (SUG) is a 
modified γ-cyclodextrin that rapidly reverses 
steroidal neuromuscular blockade after anaesthesia 
without inhibition of the enzyme acetylcholinesterase 
[11,12,2]. It is a drug with a doughnut-like molecular 
structure containing a lipophilic core and a 
hydrophilic periphery forming a complex with ROC 
or VEC that reduces their binding affinity to nicotinic 
receptors in the neuromuscular junctions [13]. SUG 
combined with ROC or VEC is well tolerated with no 
clinical evidence of residual neuromuscular blockade 
at recommended doses of SUG [14, 5]. 
In a previous study we demonstrated that 
sugammadex induces apoptosis/necrosis in neurons 
in primary culture and increases cytochrome C 
(CytC), apoptosis-inducing factor (AIF), Smac/Diablo 
and Caspase 3 (CASP-3) protein expression [15]. 
However, the combination of SUG with ROC or VEC 
has not been previously assessed. The present study 
was conducted in order to evaluate neuronal effects of 
SUG in combination with ROC or VEC 
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Material and Methods 
Materials 
All animals were handled according to the 
recommendations of the Bioethics Committee of the 
School of Medicine of the University of Valencia, 
Spain. Ethics committee specifically approved this 
study (number A1265026030697). SUG was acquired 
from Merck Millipore products (Madrid, Spain). 
Rocuronium Bromide and Vecuronium Bromide were 
obtained from Sigma Aldrich (Madrid, Spain). 
Appropriate concentrations of SUG (75 µg/ml), ROC 
(2 µg/ml) or VEC (0.33 µg/ml) were used for these 
experiments. Dulbecco’s modified Eagle’s medium 
(DMEM) and foetal bovine serum (FBS) were 
obtained from Gibco life technology (Gibco Invitrogen 
Corporation, Barcelona, Spain). 3-(4,5-dimethyl-2- 
thiazolyl)-2,5-dipheniyl-2H-tetrazolium bromide 
(MTT) was purchased from Sigma Chemical Co. (St 
Louis, MO). Western blot enhanced chemo- 
luminescent detection system (ECL) was obtained 
from Amersham Bioscience (Amersham Biosciences, 
Barcelona, Spain). Monoclonal anti-glial fibrillary 
acidic protein (anti-GFAP) antibody (1:500) was 
acquired from Sigma-Aldrich Biotech (Madrid, 
Spain). Monoclonal anti-MAP-2 protein (anti-MAP-2) 
antibody (1:500) and monoclonal anti-cytochrome C 
protein (anti-CytC) antibody (1:500) and anti-α- 
tubulin were acquired from Santa Cruz Biotechnology 
(Barcelona, Spain). Anti-apoptosis-inducing factor 
(anti-AIF) (1:500) and anti-Smac/Diablo (1:500) were 
obtained from Sigma-Aldrich Biotech. (Barcelona, 
Spain). All other reagents were of analytical or culture 
grade purity. 
Neurons in primary culture 
Primary cultures of cortical neurons were 
prepared from the cerebral cortex of 14-15-day old rat 
foetuses (5 female rats to obtain the foetuses). The 
cerebral cortex, obtained under toxin-free sterile 
conditions, was dissected and dissociated 
mechanically by pipetting 10 times with DMEM (10 
ml for the cortex obtained from 12-14 foetuses). The 
cell suspension was filtered through a nylon mesh 
with a pore size of 90 μm and plated (5 x 104 
cells/cm2) on poly-lysine-coated dishes. After the cell 
attachment (1 h), the plating medium was changed to 
DMEM pH 7.4, supplemented with 10% foetal bovine 
serum (FBS), 10 mM HEPES, 40 mM NaHCO3, 100 
units/ml penicillin, and 100 mg/ml streptomycin. 
One hour is enough to stick neurons and to avoid 
astrocytes sticking on the plate.  
After 4 days, the plating medium was changed 
with another medium prepared as described above. 
At seven days of culture, 20% FBS was changed to a 
10% solution. Cultures were grown in a humidified 
atmosphere of 5% CO2 and 95% O2, at 37oC, for 3 days, 
and then exposed to cytosine β-D arabinofuranoside 
(10 μM) for 24 h to prevent proliferation of no 
neuronal cells. Possible contamination by astrocytes 
was assessed by immuno-fluorescence using 
monoclonal anti-glial fibrillary acidic protein (GFAP) 
(astrocytes marker: Sigma-Aldrich. 1:500) antibody 
(clone G-A-5) and polyclonal anti-microtubule- 
associated protein 2 (MAP-2) (neuronal marker: 
Sigma-Aldrich. 1:500). Under these conditions 
approximately 99% ± 3% of all cultured cells were 
neurons [15]. All animal work was performed 
according to minimize animal suffering and to reduce 
the total number of animals used. 
MTT assay 
Cellular viability of the cultures was determined 
by MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide] [16]. Cells were plated 
in a 96 well culture plate and incubated with SUG, 
ROC, VEC, SUG+ROC and SUG+VEC during 24 h. 
After cell treatments, the medium was removed and 
the cortical cells were incubated with red free 
medium and MTT solution [0.5 mg/ml, prepared in 
a  phosphate buffer saline (PBS) solution] for 4 h at 
37ºC. Finally the medium was removed and formazan 
particles were dissolved in dimethyl sulfoxide 
(DMSO). Cell viability was normalized relative to 
control cells whose viability was noted as 100% when 
treated for the indicated periods with the 
corresponding vehicles. Relative amount of MTT 
reduction, was determined by spectrophotometry at 
570 nm.  
Lactate Dehydrogenase (LDH) Assay 
To evaluate plasma membrane integrity, LDH 
release was determined by monitoring the leakage of 
the cytosolic LDH to the extracellular medium. LDH 
was measured spectrophotometrically at 340 nm, 
following the rate of conversion of reduced 
nicotinamide adenine dinucleotide to oxidized 
nicotinamide adenine dinucleotide.  
Optic microscopy 
Neuron monolayers growing on culture dishes 
were used for optic microscopy studies. Photographs 
were made at the seventh day of culture. SUG, ROC 
and VEC were added 24 h before those images were 
obtained.  
Caspase 3 activity assay 
Sub-cellular fractioning of cortical neurons was 
carried out to segregate cytosol and membrane 
sections. Briefly, cells in the supernatant were 
collected by centrifugation and attached cells scraped 
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in 5 mM EDTA in PBS were pelleted by a 10 min, 4°C 
centrifugation at 1000 x g. Pellets were re-suspended 
in 200 μl of fractionation buffer (0.25 M sucrose, 1 mM 
Mg chloride, 2 mM EGTA, and 25 mM HEPES, pH 
7.4) and lysed by three cycles of flash freezing in 
liquid nitrogen. Lysates were then centrifuged at 
100000 × g for 30 min at 4oC. Supernatants (cytosol 
fraction) were separated and the pellet (membrane 
fraction) was dissolved again in 200 μl of fractionation 
buffer containing 5% Triton X-100 and briefly 
sonicated. Whole-cell lysates were obtained by 
harvesting or homogenizing the samples in 
sub-cellular fractioning buffer containing 2.5% Triton 
X-100, followed by a brief sonication. This activity was 
measured in cytosolic fractions by using a highly 
sensitive colorimetric substrate, N-acetyl-Asp-Glu- 
Val-Asp p-nitroanilide (Ac-DEVD-pNA) following 
the manufacturer’s instructions (CalBiochem, La Jolla, 
CA). Enzyme activity (pmol/min) was calculated, 
using the manufacturer’s formulae.  
Western-blots 
Attached cells (neurons in primary culture) were 
collected and harvested with pH 7.4 ice-cold buffer 
(0.125 M Tris-HCl, pH 6.8, 2% SDS, 19% glycerol, 1 
mM phenylmethylsulfonyl fluoride, 1μg/ml 
leupeptin, 1μg/ml aprotinin, and 1μg/ml pepstatin), 
and disrupted by repeated cycles of freezing and 
thawing, and then boiled for 5 min at 90º. Cell extracts 
were homogenized and centrifuged (10000 x g for 10 
min at 4ºC). The resulting supernatant was used for 
western-blot analysis. Protein concentration was 
determined using a modified Lowry method [17]. 
Proteins were separated by SDS-PAGE gels and 
transferred to nitrocellulose membranes using 
standard techniques. Membranes were blocked with 
5% dried milk in TBS containing 0.05% Tween-20 and 
then incubated with the corresponding antibodies 
following the manufacturer’s recommendations. The 
blots were washed three times, 15 minutes each cycle, 
with phosphate-buffered saline containing 0.2% 
Tween 20 and then incubated for 1 h with a secondary 
horseradish peroxidase-linked anti-rabbit or anti- 
mouse IgG antibody. ECL was used for antibody 
detection. Auto-radiographic signals were assessed 
using a Bio-Rad scanning densitometer. 
Statistical significance 
Statistical analyses were performed using the 
t-Student test and one way ANOVA with the program 
GraphPad Prism 7. p ≤ 0.05 was considered 
statistically significant.  
Results 
SUG, ROC, VEC and cell viability 
The role of SUG, ROC and VEC on cell viability 
was studied using MTT conversion assays. Figure 1 
shows that incubation with SUG (75 µg/ml) at 
different treatment times (6, 12 and 24 h) induced a 
significant decrease in neuron viability at any time 
tested compared with control cells. We choose for 
future experiments 24 h treatment time, because it 
represents the biggest decrease data compared to 
control neurons.  
In Figure 2, we show that ROC or VEC did not 
change cell viability compared to control cells. On the 
other hand, both ROC and VEC prevented the 
decrease in cell viability induced by SUG (Figure 2).  
 
 
Figure 1. Neuronal cell death induced by SUG (75 µg/ml). Time dependent 
neurotoxicity of SUG was determined by the MTT assay. Data are means ± SD 
for 4 independent experiments. *p ≤ 0.05 comparing SUG vs control (no 
additions).  
 
 
 
Figure 2. Determination of cell viability using ROC (2 µg/ml), VEC (0.33 
µg/ml), SUG (75 µg/ml), ROC+SUG (2 µg/ml and 75 µg/ml respectively), and 
VEC+SUG (0.33 µg/ml and 75 µg/ml respectively) by the MTT assay. *p ≤ 0.05 vs 
control. #p ≤ 0.05 vs SUG. Data are means ± SD for 5 independent experiments. 
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ROC and VEC did not increase LDH release 
whereas neurons incubated with SUG for 24 h 
showed a significant LDH leakage of 61.2% compared 
to control cells. The combination of SUG with ROC or 
VEC did not increase LDH release, indicating that 
ROC and VEC prevent cell death induced by SUG 
(Figure 3).  
 
 
Figure 3. LDH assay using ROC (2 µg/ml), VEC (0.33 µg/ml), SUG (75 µg/ml), 
ROC+SUG (2 µg/ml and 75 µg/ml respectively), and VEC+SUG (0.33 µg/ml and 
75 µg/ml respectively). *p ≤ 0.05 vs control. #p ≤ 0.05 vs SUG. Data are means 
± SD for 4 independent experiments. 
 
Optic microscopy after SUG, ROC and VEC 
treatment 
Using optic microscopy technique, we detected a 
decrease in cell number after 24 h of SUG treatment 
(Figure 4B) compared to control neurons (Figure 4A). 
The presence of ROC or VEC prevented the decrease 
in the number of neurons induced by SUG, Figure 4C 
and D.  
 
 
Figure 4. Optic microscopic image of cultured neurons incubated without 
drugs (A), with SUG (75 µg/ml) (B), ROC (2 µg/ml) + SUG (75 µg/ml) (C) and 
VEC (0.33 µg/ml) + SUG (75 µg/ml) (D).  
 
Caspase 3 activity  
Neither ROC nor VEC altered the caspase 3 
activity. The presence of SUG (75 µg/ml) for 24 h 
increased caspase 3 activity from 3.5 (control cells) to 
6.89 pmol/106 cells x min, indicating significant 
increase of apoptosis after SUG addition. In the 
culture medium ROC or VEC avoided caspase-3 
activity increase produced by SUG (Figure 5), which 
indicated a prevention of apoptosis when either ROC 
or VEC were present in the culture. 
 
 
Figure 5. Determination of caspase 3 activity without (C) and with ROC 
(2µg/ml), VEC (0.33 µg/ml), SUG (75 µg/ml), ROC+SUG (2 µg/ml and 75 µg/ml 
respectively), and VEC+SUG (0.33 µg/ml and 75 µg/ml respectively). *p ≤ 0.05 
vs control. #p ≤ 0.05 vs SUG. Data are means ± SD for 4 independent 
experiments. 
 
Proteins related to cell-death molecular 
signals 
Using western-blot technique shown in Figures 
6, 7 and 8 different protein levels related to cell-death 
molecular signals were determined. ROC and VEC 
did not affect cytochrome c expression in neurons in 
primary culture. Nevertheless, SUG produced an 
increase of cytochrome c expression compared with 
control neurons (Figure 6). SUG incubated with either 
ROC or VEC avoided cytochrome c overexpression 
induced by SUG.  
 
 
Figure 6. Quantitative analysis of cytochrome c. Results are expressed as 
relative changes in arbitrary units normalized against an internal standard 
(α-tubulin). Data are means ± SD (error bars) (n=5). *p ≤ 0.05 vs control; #p ≤ 
0.05 vs SUG.  
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Figure 7 shows Smac/Diablo expression in 
neurons in primary culture. ROC and VEC did not 
modify Smac/Diablo expression whereas SUG 
increased this protein. The presence of either ROC or 
VEC prevented Smac/Diablo overexpression induced 
by SUG. 
 
 
Figure 7. Results (Smac/Diablo) of quantitative analysis of immunoblots are 
means ± SD (error bars) (n=4) expressed as relative changes in arbitrary units 
normalized against an internal standard (α-tubulin). *p ≤ 0.05 vs control; #p ≤ 
0.05 vs SUG. 
 
We demonstrated in Figure 8 the increase in AIF 
protein expression after SUG addition compared to 
control cells that was prevented by co-incubation with 
either ROC or VEC. Neither ROC nor VEC alone 
managed to modify AIF expression. 
 
 
Figure 8. Results (AIF) of quantitative analysis of immunoblots are means ± SD 
(error bars) (n=5) expressed as relative changes in arbitrary units normalized 
against an internal standard (α-tubulin). *p ≤ 0.05 vs control; #p ≤ 0.05 vs SUG. 
 
Discussion 
We previously demonstrated that SUG at 
clinically significant doses, induces neuronal death by 
apoptosis/necrosis, increasing CytC, AIF, 
Smac/Diablo expression and CASP-3 activity [15]. In 
the present work, we show how ROC and VEC did 
not induce any direct effect in neurons in primary 
culture, but prevented toxic neuronal effects induced 
by SUG.  
ROC and VEC act as antagonists of the 
cholinergic receptor at neuromuscular junction and 
this effect is reversed by SUG [11]. The side chains of 
SUG bind to steroidal NMB [18,19]. The union is 
non-covalent with Van-der-Waals interactions 
playing a minor role, and positively charged groups 
of NMB electrostatically bind negatively charged end 
groups of SUG [18]. The encapsulation by SUG, 
forming a 1:1 complex with free intravascular 
steroidal NMB drugs, rapidly reduces the 
concentration of both ROC and VEC in the 
neuromuscular junction, resulting in an earlier 
reversal of the neuromuscular blockade [5]. In a study 
in healthy volunteers, the simultaneous 
administration of SUG with ROC or VEC evidenced a 
faster decrease in plasmatic concentrations of NMB 
agents than those of SUG facilitating free SUG side 
effects [14]. This could imply that, in the clinical 
setting, if SUG is administered at high doses, the 
unbound SUG molecules will remain free, increasing 
the possibility of inducing toxic effects [5]. The affinity 
of SUG for ROC is 2.5 times higher than VEC [18]. In 
this sense, the rapid onset of action and rapid reversal 
of effects by SUG makes ROC preferable to VEC 
[19,20]. 
Both ROC and VEC have hepatic and renal 
metabolism [21] and the rate of elimination of NMB 
depends on their half-life, being shorter for VEC [22]. 
SUG is eliminated unaltered via urine [23,24] and the 
inactive complex ROC-SUG or VEC-SUG is rapidly 
cleared through the kidney, according to the 
pharmacokinetic properties of SUG [25,26,5]. 
Therefore, when renal or hepatic function is impaired, 
ROC, VEC and SUG half-life and plasma 
concentration can be increased [22].  
Most frequently reported side effects of SUG 
administration are pain, nausea, coughing, headache 
or vomiting [2,10], being the hypersensitivity 
reactions, ranging from erythema to anaphylactic 
shock, are the most alarming among them [27,28,29]. 
Furthermore, allergy to NMB has been considered the 
first cause of perioperative anaphylaxis [30,31]. ROC 
could induce anaphylactic shock after induction of 
anaesthesia [32], and patients with a positive history 
of antibiotic hypersensitivity have a higher risk to 
develop intraoperative anaphylaxis [33]. ROC also has 
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the potential to interact with other drugs, including 
aminoglycosides [34]. The incidence of VEC-induced 
anaphylactic reactions is lower than those induced by 
ROC [28]. Although SUG itself could induce 
hypersensitivity reactions, it was used to stop 
anaphylaxis induction by ROC, based on SUG design 
to encapsulate ROC [35]. In previous studies, SUG has 
proven capable of reversing the increase in mast-cell 
number and degranulation caused by ROC [36].  
ROC, VEC or SUG cannot pass through a healthy 
and mature blood-brain barrier (BBB) [37,38]. 
However, there is evidence that patients with an 
impaired BBB function treated with either of these 
compounds, present autonomic dysfunction, seizures 
[39] and neuronal cell death [15]. Furthermore, ROC, 
but not VEC, has been detected in cerebrospinal fluid 
in patients with subarachnoid haemorrhage who 
underwent neurosurgery [39,40,41]. This finding 
could be attributed to the fact that ROC is more 
hydrosoluble than VEC, so it may easily arrives to 
central nervous system when BBB is damaged [42]. 
In summary, these reports highlight that clinical 
conditions which compromise the BBB integrity, such 
as Alzheimer´s disease, traumatic brain injury, brain 
ischemia or haemorrhage, meningitis, or immature 
nervous system, are susceptible of neurotoxicity 
induced by these drugs. [43,44,45].  
Aging is associated with a decline in 
physiological function, and this includes drug 
metabolism [46]. In this sense, it has been reported 
that recovery periods from ROC and VEC were 
prolonged in elderly patients [47]. Moreover, when 
SUG was used for the reversion of the neuromuscular 
blockade induced by ROC, the recovery, although 
rapid, was slightly slower in the elderly patients 
[48,49]. Also other authors suggest that SUG, 
especially for ROC, fails to return to baseline values of 
EMG in elderly people [40]. Furthermore, there is no 
data about SUG effects in pregnant women, but in 
animal studies demonstrated the presence of SUG 
levels in breast milk [50]. SUG is not recommended 
for patients under 2 years old because of the lack of 
available data in this population but the risk of 
neuronal toxicity should be taken into account for 
future research [43].  
In conclusion, the present study demonstrates 
that ROC or VEC prevents the increase of CytC, AIF, 
Smac/Diablo expression and CASP-3 activity induced 
by recommended doses of SUG in neurons in primary 
culture. Moreover, both ROC and VEC avoid cell 
death (apoptosis/necrosis) induced by SUG. This 
study suggests that it would be desirable to titrate 
SUG to the minimal effective dose in order to prevent 
excess of free SUG in plasma that could induce 
neuronal damage, especially in situations of BBB 
function impairment. 
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